ArticleNeoplasia (New York, N.Y.)2012
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Andre Cassell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this papertrialcites it